Skip to main content

Table 1 Patient and normal volunteer cohort characteristics (n = 70)

From: Cardiac magnetic resonance for asymptomatic patients with type 2 diabetes and cardiovascular high risk (CATCH): a pilot study

CharacteristicAsymptomatic patients with DM (n = 63)Healthy volunteers (n = 7)p
Age (years)66.3±4.460.4±4.10.005*
Male77.8%42.8%0.07
Body mass index (kg/m2)25.8±3.921.1±2.60.003*
DM duration (years)15.8±8.8
HbA1c (%)7.2±1.0
Cardiovascular risk factors
 Systolic blood pressure (mmHg)138.1±9.0133.3±5.30.14
 Smoking11.1%0%0.46
 High density lipoprotein (mmol/L)1.30±0.461.53±0.430.10
 Total cholesterol (mmol/L)4.10±0.715.26±0.40< 0.001*
Diabetic complications
 eGFR (ml/min/1.73 m2)76.6±18.687.9±10.60.04
 Microalbumin/creatnine ratio (mg/mmol)7.89±9.11
 Retinopathy14%
 Peripheral vascular disease1.4%
Anti-hypertensives
 Beta-blockers17.5%0%0.59
 ACE inhibitor46.0%0%0.04
 Calcium channel blockers65.1%0%< 0.01*
 Alpha-blockers7.9%0%1.00
 Diuretics7.9%0%1.00
 Angiotensin receptor blocker19.0%0%0.34
Lipid-modifying agents
 Statin61.9%0%< 0.01*
 Fibrates1.6%0%1.00
Anti-hyperglycaemic agents
 Acarbose1.6%0%1.00
 Sulfonylureas36.5%0%0.09
 SGLT2 inhibitor17.5%0%0.59
 Metformin90.5%0%< 0.01*
 DDP-4 inhibitor41.3%0%0.04
 Insulin30.2%0%0.18
 Pioglitazone22.2%0%0.33
Anti-platelet agents
 Clopidogrel6.3%0%1.00
 Aspirin23.8%0%0.33
  1. DM diabetes mellitus type 2, HbA1C glycated haemoglobin, eGFR estimated glomerular filtration rate, ACE angiotension converting enzyme, SGLT-2 sodium-glucose co-transport 2 inhibitor, DDP-4 dipeptidyl peptidase-4
  2. *p < 0.05